Latest Breaking News On - டேவிட் டேவிட்சன் - Page 5 : comparemela.com

Dive Brief: Bluebird bio on Wednesday said its experimental gene therapy for sickle cell disease is very unlikely related to a recently diagnosed case of leukemia in the one of the company s clinical trials, citing findings from an investigation into the genetic make-up of the study volunteer s tumor.  Bluebird had stopped two studies of the treatment in response to the diagnosis, which was disclosed in mid-February, and suspended sales of a related gene therapy product called Zynteglo that s approved for use in Europe.  The leukemia case, as well as the disclosure by Bluebird of cancer-like bone marrow disease in another study volunteer, renewed concerns about gene therapy safety that may be hard to quickly dispel. Bluebird s investigation into the other report of myelodysplastic syndrome remains ongoing, although the company said Wednesday it s not clear whether the participant formally meets the criteria for a diagnosis. 

Philip gregoryDavid davidsonDrug administrationRocket pharmaceuticalsDive briefChief scientific officer philipOrchard therapeuticsGene therapyபிலிப் கிரெகொரிடேவிட் டேவிட்சன்ராக்கெட் மருந்துகள்டைவ் சுருக்கமானதலைமை அறிவியல் அதிகாரி பிலிப்ஆர்சர்ட் சிகிச்சைகீந் சிகிச்சை